Candela Medical

www.syneron-candela.com

Formerly Syneron Medical, Syneron-Candela

High-Tech Company

Acquired by Apax

TECH VERTICALS

Aesthetics, Cosmetics, Dermatology, Hair Removal, Healthtech, Life Sciences, Medical Devices, MedTech

General Data

Sector	Medical Devices
Company Stage:	Revenue Growth
Established	2000
Number of Employees	715
Employees in Israel	135
Reg. Number:	abCDe

DESCRIPTION

Syneron is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite.

TECHNOLOGY

Syneron Candela has taken medical aesthetic science forward with its ELOS (Electro-Optical Synergy) technology. ELOS maximizes the synergy of conducted RF energy, which is already popular in medicine, and optical energy. Separately, optical energy and conducted RF have limited effectiveness in hair removal and treatment of skin disorders. Combined, they provide an exceptionally effective, safe and affordable methodology for a broad range of medical aesthetic treatment applications.

Products and Phases

Product	Phase
CO2RE®	FDA Approved CE Approved
The CO2RE system provides a total of six different treatment modes, including four fractional ablative treatment modes and pattern shapes, a traditional resurfacing mode and an excision mode that includes defined shape and freehand modes for minor dermal excisions. CO2RE® offers the ability to treat both superficial and deep skin layers simultaneously with precision-control over the intensity, pattern and depth of ablation.
eLase™ with Motif™	FDA Approved CE Approved
Fast, Pain Free Hair Removal Highly Effective. Safe on All Skin Types. Maximum Treatment Options eLase™ is the fastest diode laser platform to deliver safe and effective treatments on the widest variety of skin and hair types: The NEW Motif LHR hair removal modes are both effective and comfortable with increased patient safety and reduced treatment times on All Skin Types. The NEW Motif IR applicator is a safer, more efficient way of treating superficial skin texture and pore size for overall facial rejuvenation with zero downtime. The elōs Technology Advantage The eLase features proprietary elōs combined-energy technology of bi-polar radio frequency (RF) and diode laser energies. Engineered for Safety. Easy to Use & Maintain Increased selectiveity, deeper dermal penetration Less optical energy, when synergistically combined with bi-polar RF, improves the safety factor when treating all skin types The NEW elōs Motif mode enables faster treatment times compared to Laser or Light only low energy high frequency options Proprietary Active Dermal Monitoring™ feature monitors skin impedance changes during each pulse for added safety Contact cooling promotes patient comfort
The eMatrix system	FDA Approved CE Approved
The eMatrix system with Syneron’s unique Sublative™ treatment goes beyond fractional methods of skin resurfacing. The system utilizes Sublative RF™ – fractionated bi-polar radio frequency technology – to place the heat energy effectively into the dermis where it can produce significant dermal impact with minimal epidermal disruption. Intelligent Feedback System provides real time information on the energy delivery of each pulse Minimal downtime Deep dermal impact Safe and effective for all skin types Quick treatments: typically 10-20 minutes depending on area treated Short treatment protocol: 3 treatments, 4-6 weeks apart Lightweight, compact and portable table-top design
VelaShape III with Guided Mode - Top-performing Solution	FDA Approved CE Approved
VelaShape III with Guided Mode - Top-performing Solution, Now Better Than Ever VelaShape® III provides a highly effective solution for comfortable, non-invasive, body contouring for a wide range of patients and treatment areas. Cellulite and circumference reduction treatments with VelaShape III entail zero downtime and little or no discomfort. Short treatment sessions and outstanding results, from as little as a single session. The advanced software simplifies operation and minimizes technique sensitivity, further improving comfort level. The result: even more reliable and effective treatments, every time. Enjoy easier, more reliable, patient-centric operation with new Guided Mode software and advanced system design: Standardized treatment guidance – Minimizes operator dependency and allows safe delegation to operators. Step-by-step guided process – Eliminates the need to count pulses and navigate, increases motivation, reduces user fatigue, and improves the operator experience. Versatile system – Operator chooses between foot pedal or hand trigger operation, Guided Mode or Free Style; choice of 4 applicator covers. Compact, ergonomic design – Award-winning device fits in any treatment room; operator can sit or stand during treatment.
elōs Plus®	FDA Approved CE Approved
elōs Plus®, the ultimate multi application platform, provides a full range of the most in demand applications: AC for Acne Treatment LV / LVA for Vascular Lesion Treatment Motif LHR for Diode Hair Removal Motif HR / HR Plus Hair Removal - Especially for treating larger areas (i.e. legs), increased spot size enables treatment times that are two times faster SR / SRA for Color Correction and Pigmented Lesion Treatment SR / SRA Plus Color Correction & Pigmented Lesion Treatment - Larger spot size enables treatment times that are two times faster SRA Mini Ideally designed to reach smaller, "hard to reach" treatment areas Sublative Rejuvenation for Fine Lines, Wrinkles and Texture Sublime for Facial Contouring
Alex TriVantage-Q-switched Alexandrite & Laser-Pumped- Laser Technology	FDA Approved CE Approved
TriVantage’s Alexandrite TriVantage’s Alexandrite is renowned for it’s superior ability to treat greens, blues and black. New laser-pumped-laser technology makes it possible to deliver that same remarkable performance on tattoos of all colors. The 755 Q-switched laser pumps solid-state handpieces to generate Q-switched 1064 nm or 532 nm Nd:YAG wavelengths. Alex TriVantage; it’s everything you need to treat tattoos gently and effectively. Powerful Performance With a Gentle Touch By extending its pulse width Alex Tri Vantage optimizes the delivery of laser energy to the target chromophore while minimizing disruption of the skin. No Nd:YAG system can match Alex TriVantage’s gentle, 50 ns pulse envelope. Long-Pulse Mode Means More Options for Pigmented Lesions The addition of the 755 nm Long-Pulse mode makes it possible to treat a wide variety of pidermal and subdermal pigmented lesions safely and comfortably. With Alex TriVantage you can offer fast and effective treatments for common conditions like freckles, age spots, lentigines, Nevus of Ota and Café-au-Lait.
UltraShape®	FDA Approved CE Approved
UltraShape reduces abdominal circumference by mechanical disruption of fat cells. The UltraShape V3 works by emitting acoustic waves of ultrasonic energy that converge into a confined focal volume targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape V3’s energy transmits pulsed ultrasound, allowing control over temperature elevation (less than 0.5° C increase) and enabling fat destruction to occur instantly, selectively and mechanically (non-thermal).
eTwo	FDA Approved CE Approved
eTwo combines the unique Sublime and Sublative applications for comprehensive facial rejuvenation. Sublime™ uses the elōs combination of safe and effective levels of infrared light and bi-polar radio frequency energies to remodel the deep dermal layer of the skin by stimulating new collagen growth. Sublative™ fractionated bi-polar radio frequency technology places the heat energy effectively into the upper dermis where it can produce a significant increase in both collagen and elastin with minimal epidermal disruption. eTwo Advantages: Visible Results, Low Downtime Intelligent Feedback System, real time information on skin condition, impedance and the energy delivery of each pulse Safe & effective for all skin types Quick treatments: typically 20 - 40 min Short treatment protocol Lightweight, compact, multi-applicator platform Easily transports between practice locations
The GentleMax Pro®	FDA Approved CE Approved
The GentleMax Pro® is a single consolidated system that delivers a range of treatments - all skin type hair removal, as well as pigmented and vascular lesions. It is a dual wavelength laser platform that combines the fastest and most powerful 755 nm Alexandrite laser with the 1064 nm Nd:YAG laser for high performance treatment capabilities in terms of speed, efficacy, ease-of-use, outstanding performance and safety. A 20/22/24 mm Large Spot Delivery System makes the GentleMax Pro the fastest dual wavelength hair removal laser in the market. Two “Upgradeable” product configurations in the Gentle Pro Series. Each of the Upgradeable systems are direct derivatives of the GentleMax Pro system and provide the complete set of GentleMax Pro specifications for a single wavelength: The GentleLase Pro-U® long pulse alexandrite laser system can be upgraded to include the 1064nm features and The GentleYAG Pro-U® long pulse Nd:YAG laser can be upgraded to include 755nm features. The Gold Standard Gentle Hair Removal® - for All skin types Further Clinical Indications include: Epidermal pigmented lesions Sun-damaged skin Age spots Freckles Vascular anomalies Spider veins Telangiectasia on the face and legs Telangiectatic Matting Pseudofoliculitis Barbae / Beard Bumps Nail Fungus
PicoWay®	FDA Approved CE Approved
PicoWay® is a remarkably innovative dual wavelength picosecond laser with both non-fractional & fractional capabilities from Syneron Candela, the most trusted name in aesthetic lasers. PicoWay - now with Resolve - is the first picosecond dual wavelength (532nm & 1064nm) system with both non-fractional and fractional capabilities. "Picosecond lasers are already being used for skin rejuvenation and improvement of acne scarring, using fractionated and non-fractionated beam profiles"1,2. PicoWay Advantages: Provides dual wavelength (1064nm & 532nm) to target deep and shallow lesions 1st and only aesthetic laser with revolutionary holographic fractional technology Uses picosecond holographic fractional to deliver predictable energy and ensure uniform treatments Customizes treatment of pigmentation and skin and textural irregularities with adjustable fluences Easy add-on to PicoWay With the non-fractional modality, treat a wide range of tattoos 2 wavelengths to treat all tattoo1 colors & types, including recalcitrant tattoos High peak power - delivers energy over a broad range of spot sizes Short picosecond pulses - allows energy delivery with minimal risk of side effects
Profound	FDA Approved CE Approved
Profound® is clinically proven to create 3 vital skin elements: elastin, collagen and hyaluronic acid2. These major skin building blocks work to create dermal volume. Profound is the first device with temperature controlled radiofrequency clinically and scientifically proven to deliver energy directly to the deep dermis to stimulate neo-elastogenesis, neocollagenesis and hyaluronic acid deposition. Effective at Toning Lax Skin, Creating Dermal Volume 1st clinical evidence of profound neoelastogenesis2 Clinical proof of new elastin, collagen & hyaluronic acid2 Increase in reticular dermal volume2 High Physician & Patient Satisfaction 100% response rate for wrinkles3, 95% response rate for skin laxity3 47% had “significant to dramatic improvement in global skin appearance”3 Non-surgical, yet yields 37% improvement in skin laxity compared to a surgical face lift4 Natural healing response at all skin levels2. No fillers. No toxins.
The UltraShape®	FDA Approved CE Approved
The UltraShape® System is the first and only FDA cleared, non-invasive body shaping device that uses pulsed, focused ultrasound to mechanically (non-thermally) and selectively destroy fat cells at a designated focal point in the subcutaneous fat tissue without harming the skin, blood vessels, nerves or connective tissue, demonstrating measurable results in as little as 2 weeks. This unique technology answers the growing patient demand for a non-invasive body shaping solution that offers no downtime and without the complications associated with surgery.
Vbeam Perfecta®	FDA Approved CE Approved
Vbeam Perfecta® is the gold standard and the world's best selling pulsed-dye laser. Time and again it proves itself as the safe, easy-to-use tool for the treatment of vascular, pigmented and certain non-pigmented lesions with a low incidence of side effects. Vbeam Advantages - Experience Pulsed Dye Laser Leadership Widest variety of treatment spot sizes, pulse widths and treatment indications Ergonomic Smart Handpiece Intuitive Touch Screen Energy Output Versatility Patented DCD™ Cooling

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Cosmetics & Aesthetics Clinics, Medical Services, Plastic Surgery Clinics.

	BUSINESS MODEL
	B2B

COMPETITORS

Alma Lasers , Lumenis

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
66D957F6-1F7A-E111-AC59-00155D32A403		Candela Medical		Acquired/Merged
	Division	Syneron Dental Lasers	Candela Medical
7CD01E2C-207A-E111-AC59-00155D32A403	Subsidiary	Iluminage Ltd.	Candela Medical	Acquired/Merged
F51E341A-207A-E111-AC59-00155D32A403	Subsidiary	RBT (Rakuto Bio Technologies) Ltd.	Candela Medical	Acquired/Merged

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Accounting Firm
abC Defghij	Law Firm

REMARKS

Date	Remark
	Candela Corporation was formed in 1970 and Syneron Medical Ltd. was formed in 2000. Syneron-Candela was formed in 2010, when Candela Corporation and Syneron Medical Ltd. merged, bringing together two leading, innovative companies in the medical aesthetics space. In 2017 APAX Partners acquired Syneron-Candela. In 2019 Syneron-Candela rebranded as Candela Medical.

CONTACT INFO

Expand / Collapse All

Main Address: Irvine, United States

Address	3 Goodyear, Unit A
City	Irvine
State/Province	CA
Country	United States
Zip	92618

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Wayland, United States

Address	530 Boston Post Road
City	Wayland
State/Province	MA
Country	United States
Zip	01778

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Mississauga, ON, Canada

Address	6150 Kennedy Rd. Unit# 10
City	Mississauga, ON
Country	Canada
Zip	L5T 2J4

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Yoqneam, Israel

Address	Industrial Zone, Tavor Bldg., Yoqneam Ilit
POB	550
City	Yoqneam
Country	Israel
Zip	2069200

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Geoffrey S. Crouse	CEO
Mr. Tuvya Klughaupt	Managing Director
Mr. Robert Blood	Chief Legal Officer & General Counsel
Ms. Lisa A. Soderquist	Chief Human Resources Officer
Mr. Todd Van-Horn	COO
Ms. Mary Trout	President, Americas & Chief Commercial Officer
Mr. Robert Fielitz	President & Managing Director, International Operations
Mr. Robert Ruck	President, Asia Pacific
Dr. Shimon Eckhouse	Co-Founder	Agate (Advisory Board Member)
Mr. Hans Edel	Co-Founder
Dr. Michael Kreindel	Co-Founder
Mr. Avi Lior	Co-Founder	Xenia Venture Capital Ltd. (Board Member)
Mr. Moshe Mizrahy	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	CEO, Syneron Medical
abC Defghij	Board Member	COO, Syneron
abC Defghij	Board Member	Former Co-Manager, Biocom

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Jul. 17, 2017

Revenue Growth

abCDe

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Mar. 15, 2005	Second Public Offering	NASDAQ GS	abCDe	abCDe	Including Green Shoe option ($26.3m)
Aug. 05, 2004	IPO	NASDAQ GS	abCDe	abCDe	07/2017: Delisted from Nasdaq following the acquisition by Apax Partners.

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

First Round

Jun. 01, 2001

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Sold its holdings in the company for $90m
abC Defghij	Investment Company	abCDe	Sold its 11.7% holding in the company
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe	Held 5.4% of the company; 11/2005 finished selling all of his holdings in Syneron for a total of $75m.
abC Defghij	Private Investor	abCDe	Through European High-Tech Capital and Starlight Capital - both owned by the Eckhouse Foundation; Starlight holds 10.7% of the company

Seed

Sep. 01, 2000

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe	Holds 9.6% of the company

	Acquisitions made by Candela Medical

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Medica...	Oct. 08, 2015	abCDe
abC Defghij	Medica...	Feb. 19, 2014	abCDe	$11m in cash and earn out based on certain milestones of up to $4m until end of 2015.
abC Defghij	Biomed...	May. 31, 2012	abCDe
abC Defghij	Biomed...	Mar. 12, 2012	abCDe	In cash.
abC Defghij	Medica...	Feb. 08, 2012	abCDe
abC Defghij	N/A	Dec. 09, 2010	abCDe	Consists of $2.5m in net debt that Syneron assumed, plus up to $13.25m in milestone payments in 2013.
abC Defghij	N/A	Oct. 16, 2009	abCDe	In cash, plus up to $23m more based on milestones.
abC Defghij	N/A	Sep. 09, 2009	abCDe	Shares swap.
abC Defghij	Medica...	Jun. 01, 2009	abCDe	Syneron gained control in Fluorinex Active and began to consolidate Fluorinex's results from the date of control gained.
abC Defghij	N/A	Nov. 05, 2008	abCDe
abC Defghij	Medica...	Jun. 01, 2007	abCDe

	PORTFOLIO COMPANIES

Exits (5)

Company Name	Exit Type	Date Announced	Amount	Remarks
abC Defghij	Acquired	01/06/2009	abCDe	Syneron gained control in Fluorinex Active and began to consolidate Fluorinex's results from the date of control gained.
abC Defghij	Acquired	01/01/2018	abCDe
abC Defghij	Acquired	01/06/2007	abCDe
abC Defghij	Acquired	29/09/2016	abCDe
abC Defghij	Acquired	31/05/2012	abCDe

Historic Portfolio (2)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Juvenis

Ceased to Operate

Biomed

Second Round

25/03/2012

$1m

QRay

Ceased to Operate

First Round

08/10/2007

$1.5m

Holds 9% of the company

Last Updated:	abCDe
IVC Number:	abCDe